

VERSION WITH MARKINGS TO SHOW CHANGES MADE

1. (Five times amended) A method of modulating an apoptosis-inhibiting effect in a target cell or tissue of a mutant EGFR gene, comprising administering to the cell or tissue an amount of a tyrosine kinase inhibitor that is [synergistically] effective to reduce resistance to induction of apoptosis or resistance to an increased rate of apoptosis in the target cell or tissue in combination with a therapy that is effective to induce apoptosis or to increase the rate of apoptosis in the cell or tissue.

9. (Thrice amended) A pharmaceutical composition comprising a mixture of:

(A) an amount of an agent that is effective to induce apoptosis or to increase a rate of apoptosis in a target cell or tissue; and

(B) an amount of a tyrosine kinase inhibitor that is [synergistically] effective to reduce resistance to induction of apoptosis or resistance to the increased rate of apoptosis in the target cell or tissue expressing a mutant EGFR gene, the resistance being mediated by a mutant EGFR.

13. (Thrice Amended) A kit for treating cancer comprising:

(A) an amount of an agent that is effective to induce apoptosis or increase a rate of apoptosis in a target cell or tissue; and

(B) an amount of a tyrosine kinase inhibitor that is [synergistically] effective to reduce resistance to induction of apoptosis or resistance to the increased rate of apoptosis in the target cell or tissue expressing a mutant EGFR gene, the resistance being mediated by a mutant EGFR.